Medicxi Closes €400m Medicxi III Biotech Fund In 6 Weeks

European life sciences investment firm Medicxi shows institutional investor appetite for life sciences venture capital is still strong as it secures €400m in an over-subscribed offering.

Euro currency
Institutional Investors Lured by European Biotech VC

Medicxi, the European life sciences investment firm, has demonstrated that there is still a strong appetite for biotech venture financing by being able to raise €400m for a new fund, Medicxi III, in just six weeks. While its previous two funds MV1 and MG1, respectively, focused exclusively on early stage and late stage opportunities, Medicxi III will invest in both early and late stage biopharma companies across the full healthcare continuum from discovery to late stage clinical assets.

“This fundraising has not really been a pitching exercise, it has been more about fund allocation. As soon as we...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip